Table 2.

Summary of mesenchymal stem cells/platelet-rich plasma clinical trials in osteoarthritis patients from 2012 to 2018

Defect type	MSC type	Delivery system	Type of study	Results	Ref.
OA	AD-MSC	MSCs/PRP	Case series (n = 21); Final follow-up: 6 mo	Significant positive changes at MRI	Bui et al[55], 2014
OA	AD-MSC	MSCs/PRP	Case series (n = 18); Final follow-up: 24.3 mo	Clinical improvement; Function and pain improvement at 24.3 mo	Koh et al[52], 2013
OA	AD-MSC	MSCs/PRP	Case series (n = 30); Final follow-up: 24 mo	Reducing pain and improving function in patients with knee OA	Koh et al[56], 2012
OA	AD-MSC	MSCs/PRP	Case series (n = 21); Final follow-up: 24 mo	Function and pain improvement as compared with PRP only	Koh et al[57], 2014
OA	Autologous SVF	SVF/PRP	Case series (n = 21); Final follow-up: 24 mo	All patients’ scores of pain improved to > 96; and quality of life scores to > 93	Gibbs et al[58], 2015
OA	Autologous SVF	SVF/PRP	Case series (n = 10); Final follow-up: 24 mo	Cartilage thickness improvement	Bansal et al[59], 2017

OA: Osteoarthritis; AD-MSCs: Adipose-derived mesenchymal stem cells; MRI: Magnetic resonance imaging; PRP: Platelet-rich plasma; SVF: Vascular stroma of adipose tissue.